-
-
-
-
-
-
-
ORIC Pharmaceuticals, Inc. (ORIC) Misses Q2 EPS by 2c
-
-
-
-
-
-
-
Wolfe Research Reiterates Peerperform Rating on ORIC Pharmaceuticals (ORIC)
-
-
-
-
-
-
-
ORIC Pharmaceuticals (ORIC) PT Raised to $25 at H.C. Wainwright
-
-
-
-
-
-
-
This SMID biotech stock is on JPMorgan's 'Analyst Focus List'
-
-
-
-
-
-
-
ORIC Pharmaceuticals publishes enozertinib research in Cancer Research
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on ORIC Pharmaceuticals (ORIC)
-
-
-
-
-
-
-
ORIC Pharamceuticals (ORIC) PT Raised to $22 at H.C. Wainwright
-
483,184 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


